


WHAT IS CLAIMED IS:

1. A compound having the following chemical structure:



wherein:

if any R₃-R₅, R₇, R₈, R₁₁-R₁₅ is not hydrogen, R₂ or R₆ or R₉ is not methyl, or R₁₀ is not CH₂, then R₁ is selected from the group consisting of hydrogen, a halogen, COOH, C₁-C₁₂ carboxylic acids, C₁-C₁₂ acyl halides, C₁-C₁₂ acyl residues, C₁-C₁₂ esters, C₁-C₁₂ secondary amides, (C₁-C₁₂)(C₁-C₁₂) tertiary amides, C₁-C₁₂ alcohols, (C₁-C₁₂)(C₁-C₁₂) ethers, C₁-C₁₂ alkyls, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyls, C₂-C₁₂ substituted alkenyls, and C₅-C₁₂ aryls; but

if all R₃-R₅, R₇, R₈, R₁₁-R₁₃ are hydrogen, R₂, R₆, and R₉ are each methyl, and R₁₀ is CH₂, then R₁ is selected from hydrogen, a halogen, C₁-C₁₂ carboxylic acids, C₁-C₁₂ acyl halides, C₁-C₁₂ acyl residues, C₂-C₁₂ esters, C₂-C₁₂ secondary amides, (C₁-C₁₂)(C₁-C₁₂) tertiary amides, C₂-C₁₂ alcohols, (C₁-C₁₂)(C₁-C₁₂) ethers other than methyl-acetyl ether, C₂-C₁₂ alkyls, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyls, C₂-C₁₂ substituted alkenyls, and C₂-C₁₂ aryls;

R₂ and R₉ are each separately selected from hydrogen, a halogen, C₁-C₁₂ alkyl, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyl, C₂-C₁₂ substituted alkenyl, C₂-C₁₂ alkynyl, C₁-C₁₂ alcohol, C₁-C₁₂ acyl, and C₅-C₁₂ aryl;

R₃-R₅, R₇, R₈, and R₁₁-R₁₃ are each separately selected from hydrogen, a halogen, C₁-C₁₂ alkyl, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyl, C₂-C₁₂ substituted alkenyl, C₂-C₁₂ alkynyl, and C₅-C₁₂ aryl;

R₆ is selected from hydrogen, a halogen, C₁-C₁₂ alkyl, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyl, C₂-C₁₂ substituted alkenyl, and C₂-C₁₂ alkynyl;

R_{10} is selected from hydrogen, a halogen, CH_2 , C_1-C_6 alkyl, C_1-C_6 substituted alkyl, C_2-C_6 alkenyl, C_2-C_6 substituted alkenyl, C_1-C_{12} alcohol, and C_5-C_{12} aryl; and

R_{14} and R_{15} are separately selected from hydrogen, a halogen, CH_2 , C_1-C_6 alkyl, C_1-C_6 substituted alkyl, C_2-C_6 alkenyl, C_2-C_6 substituted alkenyl, C_1-C_6 alcohol, and C_5-C_6 aryl;

wherein the compound includes the prodrug esters of the above compounds, and the acid-addition salts thereof.

2. The compound of Claim 1, wherein:

R_1 is selected from hydrogen, a halogen, C_1-C_{12} carboxylic acids, C_1-C_{12} acyl halides, C_1-C_{12} acyl residues, C_2-C_{12} esters, C_2-C_{12} secondary amides, $(C_1-C_{12})(C_1-C_{12})$ tertiary amides, C_2-C_{12} alcohols, $(C_1-C_{12})(C_1-C_{12})$ ethers other than methyl-acetyl ether, C_2-C_{12} alkyls, C_1-C_{12} substituted alkyls, C_2-C_{12} alkenyls, C_2-C_{12} substituted alkenyls, and C_2-C_{12} aryls.

3. The compound of Claim 1, wherein:

R_1 is selected from the group consisting of hydrogen, a halogen, $COOH$, C_1-C_{12} carboxylic acids, C_1-C_{12} acyl halides, C_1-C_{12} acyl residues, C_1-C_{12} esters, C_1-C_{12} secondary amides, $(C_1-C_{12})(C_1-C_{12})$ tertiary amides, C_1-C_{12} alcohols, $(C_1-C_{12})(C_1-C_{12})$ ethers, C_1-C_{12} alkyls, C_1-C_{12} substituted alkyls, C_2-C_{12} alkenyls, C_2-C_{12} substituted alkenyls, and C_5-C_{12} aryls.

4. The compound of Claim 1, wherein R_1 is selected from the group consisting of C_2-C_{12} esters and C_1-C_{12} acyl residues.

5. The compound of Claim 1, wherein R_1 is selected from the group consisting of C_2-C_6 esters.

6. The compound of Claim 1, wherein R_{10} is selected from the group consisting of C_2-C_6 alkyl groups and C_2-C_6 alkenyl groups.

7. The compound of Claim 1, wherein R_3-R_5 , R_7 , R_8 , $R_{11}-R_{15}$ is each hydrogen.

8. The compound of Claim 1, wherein R_3-R_5 , R_7 , R_8 , $R_{11}-R_{15}$ is each hydrogen; R_2 , R_6 , and R_9 are each methyl; and R_{10} is CH_2 .

9. The compound of Claim 1, wherein R₁₅ is hydrogen, and R₁₄ is selected from hydrogen, a halogen, C₂-C₆ alcohols, C₂-C₆ alkyls, C₁-C₆ substituted alkyls, C₂-C₆ alkenyls, C₂-C₆ substituted alkenyls, and C₅-C₆ aryls.

10. A method of treating a disease condition selected from the group consisting of inflammation, tuberculous pleurisy, rheumatoid pleurisy, cancer, cardiovascular disease, skin redness, diabetes, transplant rejection, otitis media (inner ear infection), sinusitis, and viral infection comprising:

identifying an animal with said disease condition; and
contacting a compound to living tissue of said animal, wherein the compound is the compound of Claim 1.

11. The method of Claim 10, wherein the compound is the compound of Claim 2.

12. The method of Claim 10, wherein the compound is the compound of Claim 3.

13. The method of Claim 10, wherein the compound is the compound of Claim 4.

14. The method of Claim 10, wherein the compound is the compound of Claim 5.

15. The method of Claim 10, wherein the compound is the compound of Claim 6.

16. The method of Claim 10, wherein the compound is the compound of Claim 7.

17. The method of Claim 10, wherein the compound is the compound of Claim 8.


18. The method of Claim 10, wherein the compound is the compound of Claim 9.

19. A method of treating a disease condition selected from the group consisting of tuberculous pleurisy, rheumatoid pleurisy, cancer, cardiovascular disease, skin redness, diabetes, transplant rejection, otitis media (inner ear infection), sinusitis, and viral infection comprising:

identifying an animal with said disease condition; and

contacting a compound selected from (a) acanthoic acid, (b) (-)-pimara-9(11), 15-dien-19-ol, (c) (-)-pimara-9(11), 15-dien-19-oic acid, (d) (-)-pimara-9(11), 15-dien-19-ol 19-acetate, (e) (-)-pimara-9(11), 15-diene, and (f) the methyl ester analog of acanthoic acid, to living tissue of said animal.

20. A method of making a synthetic compound having the following chemical structure:



wherein:

R₁ is selected from the group consisting of hydrogen, a halogen, COOH, C₁-C₁₂ carboxylic acids, C₁-C₁₂ acyl halides, C₁-C₁₂ acyl residues, C₁-C₁₂ esters, C₁-C₁₂ secondary amides, (C₁-C₁₂)(C₁-C₁₂) tertiary amides, C₁-C₁₂ alcohols, (C₁-C₁₂)(C₁-C₁₂) ethers, C₁-C₁₂ alkyls, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyls, C₂-C₁₂ substituted alkenyls, and C₅-C₁₂ aryls;

R₂ and R₉ are each separately selected from hydrogen, a halogen, C₁-C₁₂ alkyl, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyl, C₂-C₁₂ substituted alkenyl, C₂-C₁₂ alkynyl, C₁-C₁₂ alcohol, C₁-C₁₂ acyl, and C₅-C₁₂ aryl;

R₃-R₅, R₇, R₈, and R₁₁-R₁₃ are each separately selected from hydrogen, a halogen, C₁-C₁₂ alkyl, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyl, C₂-C₁₂ substituted alkenyl, C₂-C₁₂ alkynyl, and C₅-C₁₂ aryl;

R₆ is selected from hydrogen, a halogen, C₁-C₁₂ alkyl, C₁-C₁₂ substituted alkyls, C₂-C₁₂ alkenyl, C₂-C₁₂ substituted alkenyl, and C₂-C₁₂ alkynyl;

R₁₀ is selected from hydrogen, a halogen, CH₂, C₁-C₆ alkyl, C₁-C₆ substituted alkyl, C₂-C₆ alkenyl, C₂-C₆ substituted alkenyl, C₁-C₁₂ alcohol, and C₅-C₁₂ aryl; and

R_{14} and R_{15} are separately selected from hydrogen, a halogen, CH_2 , C_1 - C_6 alkyl, C_1 - C_6 substituted alkyl, C_2 - C_6 alkenyl, C_2 - C_6 substituted alkenyl, C_1 - C_6 alcohol, and C_5 - C_6 aryl

wherein the compound includes the prodrug esters of the above compounds, and the acid-addition salts thereof;

comprising the steps of:

performing a Diels-Alder reaction reacting a diene having two or more rings with a dienophile compound to yield a resultant compound have three or more rings; and

yielding the synthetic compound.